
High-quality healthcare services for the lifestyles of all people

As the leading generic drug company, we strive to provide a stable supply of high-quality generic drugs and support the healthy lives of people. We are also taking on the challenge of evolving into a general healthcare company by developing new businesses.



Business results (Output) Revenue ¥ 189.0 billion Operating profit ¥ 4.0 billion ROE 6.2% ROIC 4.3% Japan generic drug business Production 1 volume Lineup of approx. 750 products Of which, 13 new products Patent applications 46 **QualityHug**_® Technology brand, winner of the Good Design Award **New businesses** Obtained marketing and manufacturing approval for the non-invasive neuromodulation

device Relivion (first in Japan)

Launched phase 3 clinical trial

Launched a digital therapeutic to

for NASH* treatment app

in September 2025

reduce alcohol consumption

Value provided to society (Outcome) Improving healthcare access Sales volume 1 billion tablets (Sawai Pharmaceutical) **Contributing to** healthcare financing Amount of reduction in healthcare costs ¥220.3 billion Share of prescription drug Approx. 8.4% **Contributing to extension** of healthy life expectancy Personal health record (PHR) management app Used by more than medical institutions **Developing talent** Employee education

and training expenses

¥ 90.89 million

(FY2024 results)

Sawai Group Holdings Integrated Report 2025 14

* Non-alcoholic steatohepatitis

(FY2024 results)

Sawai Group Holdings Integrated Report 2025